USANA Health Sciences, Inc. (USNA)

USANA's stock has been impacted by several events in the past six months. Q1 CY2025 earnings surpassed expectations, but the stock remained flat. Q2 2025 saw an increase in net sales, but a slight decline in net earnings. Preliminary Q3 2025 earnings revealed a net loss, leading to a stock slide due to weaker sales productivity and lower customer acquisition for Hiya. The official Q3 2025 report confirmed a net loss, although net sales grew, and the company is implementing cost alignment. USANA was removed from the S&P SmallCap 600 index, causing a stock drop. Analyst downgrades contributed to a consensus 'Reduce' rating.

USANA's products typically experience demand seasonality, with strong demand in the third quarter. However, in Q3 2025, sales were softer than anticipated, indicating that other factors can influence actual demand.

USANA Health Sciences, Inc. is a global health and wellness company specializing in science-based nutritional and personal care products, operating in the Medicinal Chemicals & Botanical Products sector and the broader Packaged Foods industry. Its product lines include USANA nutritional optimizers, Essentials/CellSentials, food products for weight management, and Celavive skincare. Through the acquisition of Hiya Health, USANA has expanded into children's health and wellness products, distributed via a direct-to-consumer channel. The company sells its products through retail, subscription, direct selling, and online channels.

USANA Health Sciences has a significant international presence, operating in 25 markets across the Asia Pacific, the Americas, and Europe. Mainland China is its largest market. In the second half of 2023, USANA expanded into India.

USANA is known for high-quality, science-backed products manufactured in an FDA-registered facility. It has research collaborations and is trusted by many athletes. USANA's Vitamin D supplement received the ConsumerLab.com Seal of Approval, and the company released its fifth annual sustainability report. However, its direct-selling model faces challenges due to changing consumer preferences, and recent financial losses and compensation plan issues could impact its reputation. The acquisition of Hiya Health is a strategic move to adapt to evolving consumer preferences.

Institutional investors and hedge funds own 54.25% of USANA Health Sciences' stock, with major holders including Pzena Investment Management LLC and others. Individual ownership accounts for approximately 38.8% to 40.18% of the stock. Company insiders own 0.63% of the stock.